Morgan Stanley analyst Cedar Ekblom lowered the firm's price target on Amrize to $65 from $69 and keeps an Overweight rating on the shares. The firm's base case implies a 6% revenue CAGR and a 8% EBITDA CAGR through 2030, the analyst tells investors.
